Solid Biosciences Inc. (SLDB)
NASDAQ$5.09
Market Cap
$394.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
16 of 924
Rank in Industry
12 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SLDB Insider Trading Activity
SLDB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $26,107,606 | 5 | 24 |
Sells | $298,689 | 16 | 76 |
Related Transactions
| PERCEPTIVE ADVISORS LLC | 1 | $20.15M | 0 | $0 | $20.15M | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1 | $4.03M | 0 | $0 | $4.03M |
| Adage Capital Management, L.P. | 10 percent owner | 1 | $1.91M | 0 | $0 | $1.91M |
| Kahn Clare | director | 2 | $18,366 | 0 | $0 | $18,366 |
| Ganot Ilan | director | 0 | $0 | 4 | $16,547 | $-16,547 |
| Herzich Paul | Chief Technology Officer | 0 | $0 | 2 | $26,195 | $-26,195 |
| Tan Kevin | CFO & Treasurer | 0 | $0 | 2 | $28,379 | $-28,379 |
| Brooks Gabriel | Chief Medical Officer | 0 | $0 | 2 | $31,893 | $-31,893 |
| Hanrahan Jessie | Chief Regulatory Officer | 0 | $0 | 2 | $38,015 | $-38,015 |
| Howton David T | Chief Operating Officer | 0 | $0 | 2 | $50,418 | $-50,418 |
| Cumbo Alexander | President and CEO | 0 | $0 | 2 | $107,242 | $-107,242 |
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one …
Insider Activity of Solid Biosciences Inc.
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $26.11M and sold $298,689 worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $35.12M and sold $297,764 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $20.15M. Bain Capital Life Sciences Investors, LLC (10 percent owner) — $4.03M. Adage Capital Management, L.P. (10 percent owner) — $1.91M.
The last purchase of 1,860 shares for transaction amount of $9,924 was made by Kahn Clare (director) on 2025‑03‑11.
List of Insider Buy and Sell Transactions, Solid Biosciences Inc.
| 2025-03-11 | Kahn Clare | director | 1,860 0.0023% | $5.34 | $9,924 | -8.20% | ||
| 2025-02-19 | PERCEPTIVE ADVISORS LLC | 5M 9.5155% | $4.03 | $20.15M | -8.74% | |||
| 2025-02-19 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1M 1.9031% | $4.03 | $4.03M | -8.74% | ||
| 2025-02-18 | Adage Capital Management, L.P. | 10 percent owner | 252,545 1.1857% | $7.56 | $1.91M | -9.17% | ||
| 2025-02-14 | Sale | Cumbo Alexander | President and CEO | 11,365 0.0286% | $3.96 | $45,005 | +35.98% | |
| 2025-02-14 | Sale | Tan Kevin | CFO & Treasurer | 3,164 0.008% | $3.96 | $12,529 | +35.98% | |
| 2025-02-14 | Sale | Howton David T | Chief Operating Officer | 5,561 0.014% | $3.96 | $22,022 | +35.98% | |
| 2025-02-14 | Sale | Brooks Gabriel | Chief Medical Officer | 3,256 0.0082% | $3.96 | $12,894 | +35.98% | |
| 2025-02-14 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 3,079 0.0077% | $3.96 | $12,193 | +35.98% | |
| 2025-02-14 | Sale | Herzich Paul | Chief Technology Officer | 2,688 0.0068% | $3.96 | $10,644 | +35.98% | |
| 2025-02-14 | Sale | Ganot Ilan | director | 1,711 0.0043% | $3.96 | $6,776 | +35.98% | |
| 2025-01-28 | Sale | Ganot Ilan | director | 144 0.0003% | $3.11 | $448 | +56.63% | |
| 2025-01-10 | Sale | Tan Kevin | CFO & Treasurer | 4,073 0.0109% | $3.89 | $15,849 | -0.54% | |
| 2025-01-06 | Sale | Ganot Ilan | director | 1,056 0.0028% | $4.31 | $4,551 | -7.32% | |
| 2024-12-03 | Sale | Cumbo Alexander | President and CEO | 11,114 0.0299% | $5.60 | $62,236 | -20.46% | |
| 2024-12-03 | Sale | Howton David T | Chief Operating Officer | 5,072 0.0136% | $5.60 | $28,396 | -20.46% | |
| 2024-12-03 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 4,610 0.0124% | $5.60 | $25,822 | -20.46% | |
| 2024-12-03 | Sale | Herzich Paul | Chief Technology Officer | 2,777 0.0075% | $5.60 | $15,551 | -20.46% | |
| 2024-10-21 | Sale | Brooks Gabriel | Chief Medical Officer | 2,923 0.0085% | $6.50 | $19,000 | -13.23% | |
| 2024-06-07 | Kahn Clare | director | 1,100 0.0027% | $7.67 | $8,442 | -27.30% |
Total: 70
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| PERCEPTIVE ADVISORS LLC | 11833539 15.2705% | $60.23M | 5 | 0 | <0.0001% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5034582 6.4968% | $25.63M | 1 | 0 | |
| Adage Capital Management, L.P. | 10 percent owner | 4248084 5.4819% | $21.62M | 1 | 0 | |
| Kahn Clare | director | 2960 0.0038% | $15,066.40 | 2 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | 4192216 5.4098% | $21.34M | 2 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,527,743 | 76 | 38.40% | $447.93M | |
$84,871,118 | 57 | 17.71% | $412.59M | |
$26,923,982 | 20 | -17.22% | $407.13M | |
$73,222,926 | 18 | 60.19% | $406.4M | |
$14,865,077 | 18 | -28.56% | $389.16M |
SLDB Institutional Investors: Active Positions
| Increased Positions | 51 | +54.84% | 4M | +10.69% |
| Decreased Positions | 37 | -39.78% | 3M | -9.34% |
| New Positions | 16 | New | 795,664 | New |
| Sold Out Positions | 18 | Sold Out | 1M | Sold Out |
| Total Postitions | 107 | +15.05% | 36M | +1.35% |
SLDB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Perceptive Advisors Llc | $38,608.00 | 9.09% | 6.91M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $24,207.00 | 5.7% | 4.33M | 0 | 0% | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $22,553.00 | 5.31% | 4.03M | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $20,957.00 | 4.93% | 3.75M | +1M | +36.38% | 2024-12-31 |
| Vestal Point Capital, Lp | $15,932.00 | 3.75% | 2.85M | +50,000 | +1.79% | 2024-12-31 |
| Blackrock, Inc. | $10,401.00 | 2.45% | 1.86M | +258,414 | +16.13% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $9,772.00 | 2.3% | 1.75M | -6,075 | -0.35% | 2024-12-31 |
| Vanguard Group Inc | $7,833.00 | 1.84% | 1.4M | +30,207 | +2.2% | 2024-12-31 |
| Finepoint Capital Lp | $5,373.00 | 1.27% | 961,251 | 0 | 0% | 2024-12-31 |
| Jpmorgan Chase & Co | $5,344.00 | 1.26% | 955,932 | +945,863 | +9,393.81% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.